Company intelligence / Profile preview

Biotie Therapeutics

Turku, Finland

Ownership: Private
Development stage: Other

Overview

Tozadenant, the lead candidate in Phase 3 for Parkinson's disease, demonstrated statistically significant and clinically meaningful results in Phase 2b trials, reducing average daily OFF time as an adjunct to levodopa/carbidopa treatment.[1] Neither the drug safety monitoring board nor independent expert panels identified relationships between tozadenant treatment and serious adverse events or deaths.[1]

Therapeutic areas: PsychiatryNeurologyDermatologyGastroenterology
Modalities: Small moleculeMonoclonal antibody
Industry: Biotech

Partnerships

Michael J. Fox Foundation (SYN120 support)H. Lundbeck A/S (Selincro commercialization and royalties)

Beyond the preview

Go deeper on Biotie Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biotie Therapeutics.

Explore the full profile